Epidemiology and treatment patterns of epithelial ovarian cancer

Abstract

While ovarian cancer (OC) is relatively rare, it remains one of the most fatal cancers. Lack of robust screening methods for eOC lead to detection of most cases at advanced stages, and most patients relapse following initial treatment. Areas covered: This review summarizes epidemiology and treatment patterns of epithelial ovarian cancer (eOC). MEDLINE, EMBASE, conference proceedings, and the Cochrane Library were searched using key terms and Medical Subject Headings for ovarian cancer, treatment patterns, and epidemiology to identify articles published from 2005-2015. Expert commentary: To improve early detection, future studies should focus on the identification of biomarkers that can detect asymptomatic disease. Following diagnosis and eventual relapse, response to first-line platinum appears to guide physicians' choice of subsequent therapies, but we do not understand what patients ultimately receive or its relationship to categories of response to first-line platinum. Improved understanding of later-line treatment patterns, by initial response to platinum, could correlate with overall outcomes among relapsed patients and promote development of more effective treatment guidelines. Novel treatment approaches, such as immunotherapies, would fulfill a need for an effective strategy against advanced stages of OC that results in fewer toxic side effects.

E2F6 functions as a competing endogenous RNA, and transcriptional repressor, to promote ovarian cancer stemness

“…Ovarian cancer is the leading cause of death from gynecologic malignancies, and the second most common cause of all‐cancer death, in women . Most ovarian cancer patients are diagnosed in late stages, with poor prognosis and short life span, due to drug resistance originating from cancer‐initiating cells. Ovarian cancer‐initiating cells are characterized by cell surface expression of CD44 and CD117 (ie c‐KIT), a phenotype first identified by us, and then others …”

Hypocrellin B‐loaded, folate‐conjugated polymeric micelle for intraperitoneal targeting of ovarian cancer in vitro and in vivo

“…Ovarian cancer is the leading cause of all gynecological malignancies. Late‐stage patients have a 5‐year survival rate of only 30% . However, routine treatments do not significantly improve the prognosis of patients; new treatments must be explored to enhance the treatment efficiency of ovarian cancer.…”

Chrysin attenuates progression of ovarian cancer cells by regulating signaling cascades and mitochondrial dysfunction

“…Ovarian cancer is the most lethal gynecologic oncology and the fifth leading cause of cancer-related deaths in women due to lack of early diagnosis and the prevalence of chemoresistance (Jessmon, Boulanger, Zhou, & Patwardhan, 2017;Siegel, Miller, & Jemal, 2017). Ovarian cancer can be divided into four major histological subtypes, which are serous, mucinous, endometrioid, and clear cell carcinomas (Kaku et al, 2003).…”